← Leaderboards
Brian Sworder
Stanford University
$564,903
Attributed
$564,903
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $188.3K · FY2023–25$200K$150K$100K$50K$0
'23
'24
'25
Funding mix
By agency
NIH$564,903 · 1
By mechanism
K08$564,903 · 1
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Ronald Levy$27,846,042
- Joseph C Wu$80,370,369
- Pasi A Janne$27,388,753
- Gavin J Sherlock$42,559,674
- Joshua Wiley Knowles$7,436,668
Others in their field
Other Rising Stars on “Detection”
- Alaina J Harkness · Current Innovation, Nfp$13,724,091
- Kari A Stephens · University Of Washington$9,270,394
- Nancy Glenn · Boise State University$8,000,000
- Sarah Biber · University Of Washington$7,911,975
- Shaunna Shen · Duke University$7,747,008
- Rangarajan Sampath · Siemens Healthcare Diagnostics Inc.$5,422,657
Research focus
DetectionAntigen TargetingAftercareAdverse OutcomeBioinformaticsBiomarker IdentificationB-LymphocytesCancer Personalized Profiling By Deep SequencingCancer TypeB-Cell LymphomasCareerCd19 GeneCell Free DnaCell LineageCell PhysiologyCellsChimeric Antigen ReceptorChimeric Antigen Receptor T CellsClinical TrialsCohortComputerized ToolsCytotoxicityDesignDisability
Grant awards (4)
Determinants of Resistance to Engineered T-cell Therapies Targeting CD19 in Lymphoma$188,301
K08 · FY2025 · CA · contact PI
Determinants of resistance to engineered T-cell therapies targeting CD19 in lymphoma$188,301
K08 · FY2024 · CA · contact PI
Determinants of resistance to engineered T-cell therapies targeting CD19 in lymphoma$172,946
K08 · FY2023 · CA · contact PI
Determinants of resistance to engineered T-cell therapies targeting CD19 in lymphoma$15,355
K08 · FY2023 · CA · contact PI